pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Fabhalta · news · pharmadog
← back to Fabhalta
News mentioning Fabhalta
16
stories
5d
Vertex on the verge of ‘iconic’ evolution as key kidney disease verdict looms
biospace
6d
Deaths, failed trials and other recent setbacks in the autoimmune space
biospace
16d
Verdicts for Summit/Akeso, Capricor, Vertex mark FDA’s stacked November
biospace
26d
Novartis faces $1.9B hit from Avidity fail but maintains confidence in $12B buy
biospace
Oct 23, 26
Roche puts numbers behind phase 3 kidney disease win amid blockbuster ambitions
fiercebiotech
Oct 20, 26
Pfizer makes ‘business decision’ to end phase 2 trial of autoimmune drug as program’s future uncertain
fiercebiotech
Oct 19, 26
Novartis ends mid-stage Fabhalta study in lupus, insists no efficacy or safety issues
biospace
Oct 16, 26
Novartis scraps Fabhalta study in lupus nephritis
endpoints
Sep 23, 26
Roche, Ionis RNA drug scores in kidney disease study
biopharma dive
Sep 23, 26
Roche’s phase 3 win tees up fight with Novartis for blockbuster kidney disease market
fiercebiotech
Aug 17, 26
Vera’s newly approved IgA nephropathy drug supports kidney function, like Otsuka’s Voyxact
biospace
Aug 4, 26
Vertex unfazed by competitive IgAN space as FDA verdict looms
biospace
Jul 20, 26
Bristol Myers to build ‘powerful’ AI factory; Samsung Biologics bids for peptide maker
biopharma dive
Jul 20, 26
Vertex’s IgA nephropathy drug derisked after Novartis, Vera approvals
biospace
Jul 17, 26
Jasper gets a lifeline in merger with immune drugmaker Kira
biopharma dive
Jul 17, 26
Jasper finds new purpose in merger with Kira, while offloading Tavneos rival to Mirador
fiercebiotech